Wir kümmern uns um Ihre medizinischen Zweifel
doctor image

Univ.-Prof. Dr. Michael Gnant

Chirurgie, Viszeralchirurgie, Tumorchirurgie, Intensivmedizin

Univ.-Prof. Dr. Michael Gnant ist Vorstand der Universitätsklinik für Chirurgie der Medizinischen Universität Wien.

Seine persönlichen Arbeitsschwerpunkte sind die Viszeral- und Tumorchirurgie, insbesondere auch die chirurgische Onkologie des Pankreas- und Mammakarzinoms. Als international anerkannter Chirurg und klinischer Forscher hat er nicht nur knapp 400 Originalarbeiten veröffentlicht, sondern auch viele tausend Operationen an nationalen und internationalen PatientInnen durchgeführt.

Seine Arbeiten zum Thema Mikrometastasen im Knochenmark und experimentelle Krebstherapie haben zum Teil bahnbrechende Ergebnisse erzielt, die heute PatientInnen auf der ganzen Welt zugute kommen.

Seine internationale Anerkennung spiegelt sich in zahlreichen Herausgeber- und Mitgliedschaften sowie einigen der prestigeträchtigsten Preise seines Arbeitsgebietes wider. Durch seine interdisziplinären Erfolge verfügt er über ein nationales und internationales Netzwerk, namentlich seit 2005 als Präsident der erfolgreichen Austrian Breast and Colorectal Cancer Study Group.

Akademisch ist er auch als aktueller Vorsitzender des Senats der Medizinischen Universität tätig.
Laufbahn

  • 1988 Promotion zum Dr. med. univ.

  • 1994 Facharzt für Chirurgie

  • 1997/98 Visiting Scientist, National Cancer Institute, Bethesda, MD, USA

  • 2000 Habilitation

  • 2004 Professur für Exp. Chirurgische Onkologie

  • seit 2008 Professur für Chirurgie, Medizinische Universität Wien

  • seit 2014 Vorstand der Universitätsklinik für Chirurgie Wien

Spezialisierungen

  • Chirurgie

  • Viszeralchirurgie

  • Chirurgische Intensivmedizin

  • Chirurgische Onkologie (insbesondere Pankreas- und Mamma-Karzinom)

Funktionen

  • Vorstand der Universitätsklinik für Chirurgie Wien

  • Leiter des Brustgesundheitszentrum Wien

  • Leiter des Zentrums für Perioperative Medizin der Medizinischen Universität Wien

  • stv. Leiter des Comprehensive Cancer Center Vienna

  • Präsident der Austrian Breast and Colorectal Cancer Study Group

  • Vorsitzender des Senats der Medizinischen Universität Wien

Mitgliedschaften

  • American Society of Clinical Oncology

  • American Association of Cancer Research

  • ESA - European Surgical Association

  • B.I.G. – Breast International Group

  • Österreichische Gesellschaft für Chirurgie

  • EUSOMA

  • German Cancer Society

  • European Society of Surgical Oncology

  • European Society of Organ Transplantation

  • European Liver Transplant Association

  • Austrian Society of Gastroenterology and Hepatology

  • Austrian Society of Surgical Research

  • Gesellschaft der Chirurgen in Wien

  • Austrian Society of Senology

  • Austrian Society of Surgical Oncology

  • Senologic International Society (S.I.S.)

  • International Surgical Society ISS-SIC

  • Verein zur Förderung von Wissenschaft und Forschung im AKH-Wien

  • Cancer and Bone Society

  • Early Breast Cancer Trialists Collaborative Group Oxford

  • UEMS Breast Surgery Division

Professuren / Lehraufträge

  • Medizinische Universität Wien

  • Medizinische Hochschule Hannover, Deutschland

  • National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

  • Weill-Cornell University, New York, NY, USA

  • Mayo Clinic, Rochester, MN, USA

Auszeichnungen

  • 1994 Research Award of the Austrian Society of Senology

  • 1997 Max Kade Research Award, New York

  • 2000 Best Paper Award, ESSO

  • 2000 Best Poster Award, ESSO

  • 2000 Theodor Billroth Award, Austrian Surgical Society

  • 2000 Anton von Eiselsberg Award, Van Swieten Society Vienna

  • 2000 Research Award of the First Austrian Bank

  • 2000 “Habilitationspreis für die beste Habilitation” – Verein zur Förderung von Wissenschaft und Forschung

  • 2000 Aventis-Preis

  • 2001 Theodor Billroth Preis, Austrian Surgical Society

  • 2004 Großer Zentraleuropäischer Preis der Stadt Wien für Interdisziplinäre Krebsforschung

  • 2008 Goldenes Ehrenzeichen der Ärztekammer für Wien

  • 2009 Invited Member, European Academy of Sciences

  • 2009 Claudia-von-Schilling Preis Medizinische Hochschule Hannover, Germany

  • 2012 Massachusetts General Hospital Martin Prize in Clinical Research

Publikationen
Insgesamt veröffentlichte Univ.-Prof. Dr. Michael Gnant bisher ca. 400 wissenschaftliche Originalarbeiten. Nachstehend eine Auswahl aus den letzten Jahren:

  • Gnant M, Puhlmann M, Alexander HR, Bartlett DL. Systemic Administration of a Recombinant Vaccinia Virus Expressing the Cytosine Deaminase Gene and Subsequent Treatment with 5-Fluorocytosine Leads to Tumor-specific Gene Expression and Prolongation of Survival in Mice. Cancer Res 1999; 59: 3396-3403

  • Gnant M, Puhlmann M, Bartlett DL, Alexander HR. Regional versus Systemic Delivery of Recombinant Vaccinia Virus as Suicide Gene Therapy for Murine Liver Metastases. Ann Surg 1999; 230: 352-361

  • Gnant M, Noll L, Irvine K, et al. Tumor-specific gene delivery using recombinant vaccinia virus in a lapine model of liver metastases. J Nat Cancer Inst 1999; 91:1744-50

  • Gnant M, Noll LA, Terrill RE, et al. Isolated hepatic perfusion for lapine liver metastases: Impact of hyperthermia on permeability of tumor neovasculature. Surgery 1999; 126: 890-899

  • Gnant M, Berger A, Huang J, et al. Sensitiziation of tumor necrosis factor alpha (TNF) resistant human melanoma by tumor specific in vivo transfer of the gene endcoding for Endothelial Monocyte Activating Peptide II (EMAP-II) using recombinant Vaccinia virus. Cancer Res 1999; 59:4668-74

  • Gnant M, Turner E, Alexander HR. Effects of hyperthermia and tumor necrosis factor on inflammatory cytokine secretion and procoagulant activity in endocelial cells. Cytokine 2000; 12; 339-347

  • Friedl J, Stift A, Paolini P, ..., Gnant M. Tumor antigen pulsed dendritic cells enhance the cytolytic activity of tumor infiltrating lymphocytes in human hepatocellular cancer Cancer Biother Radio 2000; 15: 477-86

  • Stift A, Friedl J, Brostjan C, ..., Gnant M. Dendritic cell based vaccination in solid organ cancer. J Clin Oncol 2003; 21: 135-142

  • Gnant M. Pancreatic Cancer Treatment. European Surgery 2003; 35: 342-343

  • Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366: 455-62

  • Gnant M. Surgical Oncology - a proud speciality. European Surgery 2006; 38/1: 2-3

  • Gnant M, Jonat W, Boccardo F, et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncology 2006; 7: 991-996

  • Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Zoledronic Acid effectively prevents Cancer treatment-induced bone loss in premnopausal women receiving adjuvant andocrine therapy for hormone responsive breast cancer. J Clin Oncol 2007; 25: 820-8

  • Steger GG, Galid A, Gnant M, et al. Pathologic complete response with 6 vs. 3 cycles of Neoadjuvant epirubicin/decetaxel + G-CSF in operable breast cancer: resutls of ABCSG-14. J Clin Oncol 2007; 25: 2012-8

  • Jakesz R, Greil R, Gnant M, et al. Extended adjuvant therapy with Anastrozole among postmenopausal breast cancer patients: Results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Canc Inst 2007; 99:1845-53

  • Poetter R, Gnant M, Kwasny W, et al. Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favourable early breast cancer. Int J Radiat Oncol 2007; 68: 334-40

  • Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncology 2008; 9:840-9.

  • Gnant M, Mlineritsch B, Schippinger W, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal breast cancer. New Engl J Med 2009; 360:679-91

  • Gnant M. To measure the unmeasurable. World J Surgery 2009; 33: 52-3

  • Gnant M, Dubsky P, Fitzal F, et al. Maintaining Bone Density in patients undergoing treatment for breast cancer: is there an adjuvant benefit? Clin Breast Cancer 2009; 9: s18-27

  • Filipits M, Rudas M, Heinzl H, ..., Gnant M. Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy. Clin Cancer Res 2009; 15: 5888-94

  • Gnant M. Bisphosphonates in the prevention of disease recurrence: Current results and ongoing trials. Curr Cancer Drug Targets 2009; 9: 824-33

  • Akan B, Sahora K, Puhalla H, Gnant M, et al.Cystic neoplasms of the pancreas: Conservative or operative treatment? Eur Surg 2009; 40:220-6

  • Gnant M, Blaha P, Dubsky P, et al. Adjuvant bisphosphonates in endocrine-responsive breast cancer: what is their place in therapy? Ther Adv Med Oncol 2009; 1: 123-36

  • Gnant M, Steger GG. Fighting overtreatment in adjuvant breast cancer therapy. Lancet 2009; 374: 2029-30 30,758

  • Dowsett M, Cuzick J, Ingle J, ..., Gnant M, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010; 28: 509-18

  • Gnant M, Dubsky PC. Closing in on the unknown enemy. Lancet Oncol 2010; 11:402-3

  • Neville-Webbe H, Gnant M, Coleman R. Potential anticancer properties of bisphosphonates. Semin Oncol 2010; 7: S53-65

  • Gnant M. Adjuvant Zoledronic Acid reduces disease recurrence in breast cancer: Antitumor effects on the seed and the soil. Curr Cancer Ther Rev 2011; 7: 111-18

  • Kerjaschki D, Bago-Horvath Z, Rudas M, ..., Gnant M, et al. Lipoxigenase mediates invasion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenografts in mouse. J Clin Invest 2011; 132: 2000-12

  • Sahora K, Kuehrer I, Fitzal F, Schindl M, Koelblinger C, Goetzinger P, Gnant M. NeoGemTax - Gemcitabine and docetaxel as neoadjuvant treatment for locally advanced non-metatasized pancreatic cancer. World J Surg 2011; 35: 1580-9

  • Gnant M, Mlineritsch B, Stoeger H, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early breast cancer: 62-month follow-up from ABCSG-12. Lancet Oncol 2011; 12: 631-41

  • Filipits M, Rudas M, Jakesz R, ..., Gnant M. A new molecular predictor of distant recurrence in estrogen recpetor-positive HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 2011; 17: 6012-20

  • Öfner D, DeVries A, Schaberl-Mosef R, ..., Gnant M, Thaler J. Preoperative oxaliplatin, capecitabine and external beam readiotherapy in patients with newly diagnosed, primary operable, cT3NxM0 low rectal cancer - a Phase II study. Strahlenther Oncol 2011; 187: 100-7

  • Gnant M, Piccart-Gebhart M, Goldhirsch A, et al. Developing an international network for breast cancer research: the Breast International Group (BIG) experience. Clin Invest 2011; 1(5): 623-28

  • Pfeiler G, Koenigsberg R, Fesl C, ..., Gnant M. Impact of Body Mass Index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: An analysis of the prospective ABCSG-12 trial. J. Clin Oncol 2011; 29: 2653-9

  • Gnant M. Targeted therapies: Adjuvant bisphosphonates - an option with low estrogen? Nature Reviews Clinical Oncology 2011; 8: 698-9

  • Sahora K, Kuehrer I, Eisenhut A,..., Gnant M. NeoGemOx - Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced non-metastasized pancreatic cancer. Surgery 2011; 143: 311-20

  • Gnant M, Steger GG. Dual HER2 inhibition in breast cancer treatment. Lancet 2012; 379; 596-8

  • Kaufmann M, von Minckwitz G, Mamounas EP, ..., Gnant M, et al. Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer. Ann Surg Oncol 2012; 19: 1508-16

  • Hadji P, Aapro M, Costa L, Gnant M. Antiresorptive treatment options and bone health in cancer patients - safety profile and clinical considerations. Cancer Treatm Rev 2012; 38, 815-24

  • Baselga J, Campone M, Piccart M, ..., Gnant M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Eng J Med 2012; 366: 520-9

  • Hadji P, Gnant M, Body JJ, et al. Cancer treatment-induced bone loss in premenopausal women: A need for therapeutic intervention? Cancer Treatm Rev 2012; 38: 798-806

  • Gnant M, Dubsky P, Hadji P. Bisphosphonates: prevention of bone metastases in breast cancer. Recent Results Cancer Res. 2012;192:65-91

  • Barrios C, Forbes JF, Jonat W, ..., Gnant M, et al. The sequential use of endocrine treatment for advanced breast cancer: where are we? Ann Oncol 2012; 23: 1378-86

  • Fitzal F, Mittlboeck M, Steger G, ... Gnant M. Neoadjuvant chemotherapy increases the rate of breast conservation on lobular-type breast cancer patients Ann Surg Oncol 2012; 19: 519-26

  • Dubsky P, Jakesz R, Mlineritsch B, ..., Gnant M. Taxoxifen and Anastrozole as a sequencing strategy: A randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer: Final results from ABCSG-8. J Clin Oncol 2012; 30: 722-8

  • Bartsch R, Steger G, Gnant M. Bevacizumab - an unlikely comeback in breast cancer? Lancet Oncol 2015

  • Coleman RE, Gnant M, Morgan G, Clezardin P. Bone Targeted Agents: Effects on disease progression and mortality in solid tumour and haematological cancers. J Nat Cancer Inst 2012; 104: 1059-1067

  • Hadji P, Coleman R, Gnant M, Green J. The impact of menopause on bone and implications for breast cancer growth and metastasis. Ann Oncol 2012; 23: 2782-90

  • Gnant M, Clezardin P. Direct and indirect Anticancer Activity of Bisphosphonates: A review of published literature. Cancer Treatm Rev 2012; 38: 407-15

  • Gnant M. Adjuvant bisphosphonates: a new standard of care? Curr Opin Oncol 2012, 24:635-42

  • Gnant M. The Role of Mammalian Target of Rapamycin (mTOR) Inhibition in the Treatment of Advanced Breast Cancer. Curr Oncol Rep 2013; 15: 14-23

  • Hadji P, Coleman R, Gnant M. Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus. Crit Rev Oncol Hematol 2013; 101-11

  • Gnant M, Baselga J, Rugo HS, et al. Everolimus reduced bone marker levels and progressive disease in bone in BOLERO-2. J Nat Cancer Inst 2013; 105: 654-63

  • Sahora K, Schindl M, Kuehrer I, ..., Gnant M. Gemcitabine-based neoadjuvant chemotherapy for locally advanced pancreatic cancer does not affect mortality and morbidity after pancreatic resection. European Surgery 2013; 45,169-78

  • Gnant M. Role of Bisphosphonates in postmenopausal women with breast cancer. Cancer Treatm Rev 2014; 40: 476-84

  • Gnant M, Filipits M, Greil R, et al. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 score in 1,478 postmenopausal patients of the ABCSG-08 trial treated with adjuvant endocrine therapy alone. Ann Oncol 2014; 25: 339-45

  • Harmuth S, Wewalka M, Holst JJ, ..., Gnant M, Miholic J. Distal gastrectomy in pancreaticoduodenectomy is associated with accelerated gastric emptying, enhanced postprandial release of GLP-1, and improved insulin sensitivity. J Gastrointest Surg 2014; 18: 52-9

  • Gnant M, Bartsch R, Steger GG. HER2-positive breast cancer: a new piece of the puzzle. Lancet Oncol 2014; 15: 668-9

  • Rugo HS, Pritchard KI, Gnant M, et al. Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone-receptor-positive advanced breast cancer: insights from BOLERO-2. Ann Oncol 2014; 25: 808-15

  • Filipits M, Nielsen T, Rudas M, ..., Gnant M. The PAM50 risk-of-recurrence (ROR) score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer: A study on 1,246 patients from the ABCSG-8 trial. Clin Cancer Res 2014; 20: 1298-305

  • Bartsch R, Frings S, Marty M, ..., Gnant M, et al. Present and Future Breast Cancer Management - Bench to Bedside and Back: A Positioning Paper of Academia, Regulatory Authorities and Pharmaceutical Industry. Ann Oncol 2015; 25: 773-80

  • Panhofer P, Ferenc V, Schütz M, ..., Gnant M, Fitzal F. Standardization of morbidity assessment in breast cancer surgery using the Clavien Dindo Classification. Int J Surg 2014; 12: 334-9

  • Steger GG, Greil R, Lang A, ..., Gnant M. Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24). Ann Oncol 2014; 25:366-71

  • Tamandl D, Sahora K, Prucker J, Schmid R, Holst JJ, Miholic J, Goetzinger P, Gnant M. Impact of the reconstruction method on delayed gastric emptying after pylorus-preserving pancreaticoduodenectomy: A prospective randomized study. World J Surg 2014; 38:465-75

  • Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 2014; 383: 2127-35

  • Gangl O, Sahora K, Kornprat P, ..., Gnant M, Fuegger R. Preparing for prospective clinical trials - a national initiative of an excellence registry for consecutive pancreatic cancer resections. World J Surg 2014; 38: 456-62

  • Sahora K, Schindl M, Kuehrer I, ..., Gnant M. A phase II trial of two durations of bevacizumab added to neoadjuvant gemcitabine for borderline and locally advanced pancreatic cancer. Anticancer Res 2014; 34: 2377-84

  • Heitzer E, Mach M, Filipits M, ..., Gnant M, et al. Promoter methylation status of PCDH10, SPARC, and UCHL1 predict survival in stage II colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. Modern Pathology 2014; 27: 906-15

  • Piccart M, Hortobagyi GN, Campone M, ..., Gnant M, et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann Oncol. 2014; 25: 2357-62

  • Zardavas D, Maetens M, Irrthum A, ..., Gnant M, et al. The AURORA initiative for metastatic breast cancer. Br J Cancer. 2014; 111: 1881-7

  • Gnant M, Mlineritsch B, Stoeger H, et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozole plus ovarian function suppression in premenopausal early breast cancer: of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann Oncol 2015; 26; 313-20

  • Markopoulos C, Neven P, Tanner M, ..., Gnant M, et al. Does patient education work in breast cancer? Final results from the global CARIATIDE study. Future Oncol. 2015; 11: 205-17

  • Gnant M, Steger GG, Bartsch R. CDK4/6 inhibitors in luminal breast cancer Lancet Oncol 2015; 16: 2-3

  • Sestak I, Cuzick J, Dowsett M, ..., Gnant M. Prediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis of Patients From the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination Randomized Trials Using the PAM50 Risk of Recurrence Score. J Clin Oncol 2015; 33: 916-22

  • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)*. Patient-level meta-analysis of randomised trials of aromatase inhibitors versus tamoxifen in 31,920 postmenopausal women with ER-positive early breast cancer. Lancet 2015

  • Foedermayr M, Sebesta M, Rudas M, ..., Gnant M, et al. Association of TP53 mutations with TP53 codon 72 polymorphism and outcome in triple-negative breast cancer patients. J Hum Genetics 2015

  • Coleman R, Powles T, Paterson A, Gnant M, et al. Adjuvant bisphosphonate treatment in early breast cancer: Meta-analyses of individual patient data from randomised trials. Lancet 2015; 386: 1353-61

  • Fitzal F, Filipits M, Rudas M, ..., Gnant M. The genomic expression test Endopredict® is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomized within the prospective ABCSG 8 trial. Br J Cancer 2015; 112: 1405-10

  • Gnant M, Sestak I, Filipits M, et al. Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor positive early stage breast cancer treated with endocrine therapy: A combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and Intrinsic Subtype. Ann Oncol 2015

  • Bartsch R, Berghof AS, Vogl U, ..., Gnant M, Steger GG, Preusser M. Activity of T-DM1 in HER2-positive breast cancer brain metastases. Clin Exp Metastasis 2015

  • Hadji P*, Coleman RE*, Wilson C, ..., Gnant M, et al. Adjuvant bisphosphonates in early breast cancer: Consensus guidance for clinical practice from a European Panel. Ann Oncol 2016

  • Chan A, Finkelstein D, Delaloge S, ..., Gnant M, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer. Lancet Oncology 2015

  • Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thuerlimann B, Senn JH, and Panel Members. Tailoring therapies - improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 2015

  • Gnant M, Pfeiler G, Dubsky PC, et al. Adjuvant Denosumab in Breast Cancer - a multicentre, randomised, double-blind, placebo-controlled trial (ABCSG-18). Lancet 2015; 386: 433-43

  • Gnant M, Thomssen C, Harbeck N. St. Gallen/Vienna 2015: A Brief Summary of the Consensus Discussion. Breast Care (Basel) 2015

  • Blank PR, Filipits M, Dubsky P, ..., Gnant M. Cost-Effectiveness of prognostic gene expression signature-based stratification of early breast cancer patients. Pharmacoeconomics 2015; 33: 179-90

  • Gnant M. Operative Radikalität in der Diskussion. Schw Zeitschr Onkol 2015; 2: 31-3

  • Gnant M. Targeting bone microenvironment: Clinical implications. Breast 2015

  • de Leede EM, Poston GJ, Gnant M, et al. Common variables in European pancreatic cancer registries: the introduction of the EURECCA pancreatic cancer project.

  • Steger G, Gnant M, Bartsch R. Palbociclib for the treatment of postmenopausal breast cancer - an update. Expert Opinion on Pharmacotherapy 2015

  • Bartsch R, Steger G, Gnant M. Bevacizumab - an unlikely comeback in breast cancer? Lancet Oncol 2015

We are mentioned in

WordPress Image Lightbox Plugin